Carcinoembryonic Antigen is the Preferred Biomarker for in Vivo Colorectal Cancer Targeting

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Jan 17

PMID 23322207

Citations 81

Authors

J P Tiernan

S L Perry

E T Verghese

N P West

S Yeluri

D G Jayne

T A Hughes

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer-specific biomarkers have been used as molecular targets for fluorescent intra-operative imaging, targeted PET/MRI, and selective cytotoxic drug delivery yet the selection of biomarkers used is rarely evidence-based. We evaluated sensitivities and specificites of four of the most commonly used markers: carcinoembryonic antigen (CEA), tumour-associated glycoprotein-72 (TAG-72), folate receptor-α (FRα) and Epithelial growth factor receptor (EGFR).

Methods: Marker expression was evaluated semi-quantitatively in matched mucosal and colorectal cancer tissues from 280 patients using immunohistochemistry (scores of 0-15). Matched positive and negative lymph nodes from 18 patients were also examined.

Results: Markers were more highly expressed in tumour tissue than in matched normal tissue in 98.8%, 79.0%, 37.1% and 32.8% of cases for CEA, TAG-72, FRα and EGFR, respectively. Carcinoembryonic antigen showed the greatest differential expression, with tumours scoring a mean of 10.8 points higher than normal tissues (95% CI 10.31-11.21, P<0.001). Similarly, CEA showed the greatest differential expression between positive and negative lymph nodes. Receiver operating characteristic analyses showed CEA to have the best sensitivity (93.7%) and specificity (96.1%) for colorectal cancer detection.

Conclusion: Carcinoembryonic antigen has the greatest potential to allow highly specific tumour imaging and drug delivery; future translational research should aim to exploit this.

Citing Articles

Development of Anti-CEA C2 Domain-Deleted Antibody (M5A∆C2) for the PET Imaging of Colorectal Cancer.

Jitender J, Hong T, Sherman A, Wong P, Aniogo E, Kujawski M Mol Imaging Biol. 2025; .

PMID: 40085171 DOI: 10.1007/s11307-025-01997-3.

A case of neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review.

Han W, Rexiati N, Yu F, Wang Y, Tian Y, Wu J Front Oncol. 2025; 15:1508410.

PMID: 39926281 PMC: 11802412. DOI: 10.3389/fonc.2025.1508410.

The combined evaluation of preoperative serum CEA and postoperative tissue CEA as a prognostic factor in stages 0-IV colorectal cancer: a retrospective cohort study.

Tong G, Li H, Shen Y, Tan Z, Qian H Front Med (Lausanne). 2025; 11():1447041.

PMID: 39830382 PMC: 11739305. DOI: 10.3389/fmed.2024.1447041.

Tumour Marker Expression in Head and Neck Malignancies to Identify Potential Targets for Intraoperative Molecular Near-Infrared Imaging.

Lauwerends L, Zweedijk B, Galema H, Neijenhuis L, Dekker-Ensink N, Baatenburg de Jong R Mol Diagn Ther. 2024; 28(6):811-820.

PMID: 39251469 PMC: 11512873. DOI: 10.1007/s40291-024-00742-w.

A Concept for Preoperative and Intraoperative Molecular Imaging and Detection for Assessing Extent of Disease of Solid Tumors.

Hitchcock C, Chapman G, Mojzisik C, Mueller Jr J, Martin Jr E Oncol Rev. 2024; 18:1409410.

PMID: 39119243 PMC: 11306801. DOI: 10.3389/or.2024.1409410.

References

Yang S, Lin F, Tsai K, Wei M, Tsai H, Wong J . Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconjug Chem. 2010; 21(4):679-89. DOI: 10.1021/bc9004798. View

Li P, Wang Y, Zeng F, Chen L, Peng Z, Kong L . Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydr Res. 2011; 346(6):801-6. DOI: 10.1016/j.carres.2011.01.027. View

Spano J, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R . Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2004; 16(1):102-8. DOI: 10.1093/annonc/mdi006. View

Qi S, Miao Z, Liu H, Xu Y, Feng Y, Cheng Z . Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors. Bioconjug Chem. 2012; 23(6):1149-56. DOI: 10.1021/bc200596a. View

Maraqa L, Cummings M, B Peter M, Shaaban A, Horgan K, Hanby A . Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res. 2008; 14(2):405-11. DOI: 10.1158/1078-0432.CCR-07-1363. View

Chen W, Khazaie K, Zhang G, Weissleder R, Tung C . Detection of dysplastic intestinal adenomas using a fluorescent folate imaging probe. Mol Imaging. 2005; 4(1):67-74. DOI: 10.1162/15353500200504199. View

Tang Y, Yang S, Gariepy J, Scollard D, Reilly R . Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49. Bioconjug Chem. 2007; 18(3):677-84. DOI: 10.1021/bc060260r. View

Koretz K, Schlag P, Moller P . Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch A Pathol Anat Histopathol. 1990; 416(4):343-9. DOI: 10.1007/BF01605295. View

Carrasquillo J, Pandit-Taskar N, ODonoghue J, Humm J, Zanzonico P, Smith-Jones P . (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011; 52(8):1173-80. PMC: 3394182. DOI: 10.2967/jnumed.110.086165. View

10.

Sharkey R, Cardillo T, Rossi E, Chang C, Karacay H, McBride W . Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med. 2005; 11(11):1250-5. DOI: 10.1038/nm1322. View

11.

Yazaki P, Kassa T, Cheung C, Crow D, Sherman M, Bading J . Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol. 2008; 35(2):151-8. PMC: 3195408. DOI: 10.1016/j.nucmedbio.2007.10.010. View

12.

Muguruma N, Ito S, Bando T, Taoka S, Kusaka Y, Hayashi S . Labeled carcinoembryonic antigen antibodies excitable by infrared rays: a novel diagnostic method for micro cancers in the digestive tract. Intern Med. 1999; 38(7):537-42. DOI: 10.2169/internalmedicine.38.537. View

13.

Heine M, Nollau P, Masslo C, Nielsen P, Freund B, Bruns O . Investigations on the usefulness of CEACAMs as potential imaging targets for molecular imaging purposes. PLoS One. 2011; 6(12):e28030. PMC: 3230612. DOI: 10.1371/journal.pone.0028030. View

14.

Meredith R, Khazaeli M, Plott W, Grizzle W, Liu T, Schlom J . Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996; 2(11):1811-8. View

15.

Vigor K, Kyrtatos P, Minogue S, Al-Jamal K, Kogelberg H, Tolner B . Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials. 2009; 31(6):1307-15. DOI: 10.1016/j.biomaterials.2009.10.036. View

16.

Meller B, Rave-Franck M, Breunig C, Schirmer M, Baehre M, Nadrowitz R . Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells. Strahlenther Onkol. 2011; 187(2):120-6. DOI: 10.1007/s00066-010-2191-5. View

17.

Reddy J, Low P . Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst. 1999; 15(6):587-627. View

18.

Conaghan P, Ashraf S, Tytherleigh M, Wilding J, Tchilian E, Bicknell D . Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br J Cancer. 2008; 98(7):1217-25. PMC: 2359646. DOI: 10.1038/sj.bjc.6604289. View

19.

Boerman O, Oyen W . Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med. 2011; 52(8):1171-2. DOI: 10.2967/jnumed.111.089771. View

20.

Johnson V, Schlom J, Paterson A, Bennett J, Magnani J, Colcher D . Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986; 46(2):850-7. View